PT755249E - Utilizacao de inibidores da reaccao de maillard para o tratamento de doenca com base em amiloidose - Google Patents

Utilizacao de inibidores da reaccao de maillard para o tratamento de doenca com base em amiloidose

Info

Publication number
PT755249E
PT755249E PT95915254T PT95915254T PT755249E PT 755249 E PT755249 E PT 755249E PT 95915254 T PT95915254 T PT 95915254T PT 95915254 T PT95915254 T PT 95915254T PT 755249 E PT755249 E PT 755249E
Authority
PT
Portugal
Prior art keywords
amiloidose
maillard reaction
disease treatment
based disease
reaction inhibitors
Prior art date
Application number
PT95915254T
Other languages
English (en)
Inventor
Camilo Colaco
Bruce Joseph Roser
Original Assignee
Elan Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10753465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT755249(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Drug Delivery Ltd filed Critical Elan Drug Delivery Ltd
Publication of PT755249E publication Critical patent/PT755249E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT95915254T 1994-04-13 1995-04-13 Utilizacao de inibidores da reaccao de maillard para o tratamento de doenca com base em amiloidose PT755249E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9407305A GB2288732B (en) 1994-04-13 1994-04-13 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
PT755249E true PT755249E (pt) 2004-08-31

Family

ID=10753465

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95915254T PT755249E (pt) 1994-04-13 1995-04-13 Utilizacao de inibidores da reaccao de maillard para o tratamento de doenca com base em amiloidose

Country Status (11)

Country Link
US (2) US5891873A (pt)
EP (1) EP0755249B1 (pt)
JP (1) JPH09512005A (pt)
AT (1) ATE262895T1 (pt)
AU (1) AU2219795A (pt)
DE (1) DE69532804T2 (pt)
DK (1) DK0755249T3 (pt)
ES (1) ES2216012T3 (pt)
GB (1) GB2288732B (pt)
PT (1) PT755249E (pt)
WO (1) WO1995028151A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DE69332105T2 (de) * 1992-09-29 2003-03-06 Inhale Therapeutic Systems, San Carlos Pulmonale abgabe von aktiven fragmenten des parathormons
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
EP0748213B1 (en) * 1994-03-07 2004-04-14 Nektar Therapeutics Methods and compositions for pulmonary delivery of insulin
GB2288732B (en) * 1994-04-13 1998-04-29 Quadrant Holdings Cambridge Pharmaceutical compositions
WO1995031479A1 (en) * 1994-05-18 1995-11-23 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5780513A (en) * 1996-08-22 1998-07-14 Washington University Method of inhibiting the release of bioactive IL-1
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US20030035778A1 (en) * 1997-07-14 2003-02-20 Robert Platz Methods and compositions for the dry powder formulation of interferon
JPH1143432A (ja) * 1997-07-25 1999-02-16 Biremo Sci:Kk 脳の老化抑制及び治療剤
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
EP1053749A4 (en) * 1998-02-03 2003-01-15 Senju Pharma Co PREVENTION AND MEDICINE FOR NEURODEGENERATIVE DISEASES
GB9916316D0 (en) 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
AU6234700A (en) * 1999-07-27 2001-02-13 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2001085136A2 (en) 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
WO2002009674A2 (en) * 2000-07-28 2002-02-07 Inhale Therapeutic Systems, Inc. Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
JP2005514393A (ja) 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
AU2006251832A1 (en) * 2005-05-27 2006-11-30 Queen's University At Kingston Treatment of protein folding disorders
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
CA2665567C (en) * 2006-10-06 2012-07-03 Amgen Inc. Stable formulations
CA2666492C (en) * 2006-10-20 2012-07-17 Douglas Rehder Stable polypeptide formulations
US11517613B2 (en) 2017-06-07 2022-12-06 Amano Enzyme Inc. Lactase bulk powder and lactase preparation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325936A3 (en) * 1988-01-16 1990-01-17 Ono Pharmaceutical Co., Ltd. Aminoguanidine derivatives and inhibitory agents on maillard reaction containing them as active ingredients
JPH03161441A (ja) * 1989-11-20 1991-07-11 Senjiyu Seiyaku Kk メイラード反応阻害剤
JP2854631B2 (ja) * 1989-11-21 1999-02-03 千寿製薬株式会社 糖尿病合併症および老化によって引き起こされる疾患の予防・治療剤
CA2030718C (en) * 1989-11-28 1998-05-12 Jacob Berger Tricyclic compounds
KR920700632A (ko) * 1990-02-19 1992-08-10 요시다 쇼오지 메일라드 반응저해제
JP3298875B2 (ja) * 1990-03-02 2002-07-08 オレゴン州 三置換―および四置換グアニジン類およびそれらの興奮性アミノ酸アンタゴニストとしての用途
US5112596A (en) * 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
DE69233479T2 (de) * 1991-02-08 2006-03-16 Scion Pharmaceuticals, Inc., Medford Substituierte Guanidine und Derivate hiervon als Modulatoren der Freisetzung von Neurotransmittern und neue Methode zur Identifizierung von Inhibitoren der Neurotransmitter-Freisetzung
TW221689B (pt) * 1991-08-27 1994-03-11 Otsuka Pharma Co Ltd
US5453514A (en) * 1992-12-25 1995-09-26 Yamanouchi Pharmaceutical Co., Ltd. Pyrazole derivatives and compositions and methods of use as maillard reaction inhibitors
JPH09511492A (ja) * 1994-02-03 1997-11-18 ザ ピコワー インスティテュート フォア メディカル リサーチ アミロイドーシスの前進性グリコシル化終末産物仲介モジュレーション用組成物及び方法
GB2288732B (en) * 1994-04-13 1998-04-29 Quadrant Holdings Cambridge Pharmaceutical compositions

Also Published As

Publication number Publication date
GB2288732B (en) 1998-04-29
WO1995028151A1 (en) 1995-10-26
DK0755249T3 (da) 2004-07-26
US5891873A (en) 1999-04-06
DE69532804D1 (de) 2004-05-06
ES2216012T3 (es) 2004-10-16
US6034080A (en) 2000-03-07
GB9407305D0 (en) 1994-06-08
JPH09512005A (ja) 1997-12-02
GB2288732A (en) 1995-11-01
AU2219795A (en) 1995-11-10
EP0755249A1 (en) 1997-01-29
EP0755249B1 (en) 2004-03-31
ATE262895T1 (de) 2004-04-15
DE69532804T2 (de) 2005-02-10

Similar Documents

Publication Publication Date Title
PT755249E (pt) Utilizacao de inibidores da reaccao de maillard para o tratamento de doenca com base em amiloidose
EE04221B1 (et) Östrogeeni kasutamine ravimi valmistamiseks füüsiliste seisundite raviks menopausijärgsetel isikutel
TR199701212T1 (xx) �drar� tutamama halinin tedavisi i�in alfa IL- agonistlerinin kullan�lmas�.
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
IT1293690B1 (it) Stent per angioplastica, particolarmente per il trattamento di lesioni aorto-ostiali ed ostiali.
PT1052905E (pt) Processo anti-germinativo de tuberculos e bolbos utilizando o eugenol e/ou o isoeugenol
EP0685219A3 (de) Haarbehandlungsmittel und Verfahren zur Anwendung.
TR199900505T2 (pt)
IT1240486B (it) Procedimento di ammollo enzimatico per pelli e pellami.
BR9612283A (pt) Composição para o tratamento de manchas em peças de roupa e métodos de tratamento
ZA978639B (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections.
PL316656A1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
EP0681787A3 (en) Use of an enzyme for the manufacture of an agent suitable for the treatment and / or prophylaxis of coccidiosis.
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
ZA98420B (en) Use of pramipexole in the treatment of restless legs syndrome.
GB9916729D0 (en) Fuller for the treatment of leather,pelts and the like
DE60235132D1 (de) Sojaprodukte enthaltende Zusammensetzungen
NO20005548D0 (no) Mykobakterieinhibitorer
PT1052991E (pt) Utilizacao de loperamida para o tratamento de infeccoes microbianas
MD980129A (en) Antiherpetic remedy
GB9723824D0 (en) Cytostatic agents
BR0012380A (pt) 2-amino-benzoxazinonas para o tratamento de vìrus do herpes simples
SE9403861D0 (sv) Novel medicinal use
FR2786099B1 (fr) Nouvelle application therapeutique de la 1,6-dimethyl-8beta- hydroxymethyl-10alpha-methoxyergoline
IL91582A0 (en) Compositions for treating acne,for disinfecting the skin and the hair and for treating the hair